Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.

No abstract

No abstract

No abstract

No abstract

No abstract

No abstract

The reaction between bis(trialkyltin) chalcogenides and trimethylaluminum results in the formation of bis(dimethylaluminum) chalcogenides, (Me2Al)2E, where E is S, Se, or Te. Reaction between the latter and carbonyl groups (but not carboxylic acids or esters) converts them to carbon−chalcogen double-bond (CE) compounds. Using this procedure, we have successfully synthesized several telluro- and selenocarbonyl compounds. The first successful synthesis of an isolable, crystalline telluroformamide, 4-(telluroformyl)morpholine (3c, C5H9NOTe), and its crystal structure are reported. Also, the syntheses and crystal structures of a γ-tellurolactam, 1-methyl-2-telluroxopyrroline (3d, C5H9NTe), and two selenoamides, N,N-diphenylselenoformamide (3a, C13H11NSe) and N-methyl-N-(4-nitrophenyl) selenoformamide (3b, C8H8N2O2Se) are described.